Liquid biopsy to monitor LMS treatment and resistance
Official title: PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMS
Funded at University of Michigan at Ann Arbor · NIH-11419797 · Data updated 2026-11-12
A patient-centered look at using blood tests to see how well LMS treatment is working and when resistance to therapy appears.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 16, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $493,801 |
| NIH project number | 5P50CA272170-05 |
| Project ID | NIH-11419797 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with leiomyosarcoma (LMS) who are receiving standard chemotherapy.
✕Less likely to help
Patients not undergoing chemotherapy or those without LMS may not benefit from this approach.
What this research studies
This project uses a simple blood test approach to track leiomyosarcoma progression and response during standard chemotherapy. By collecting blood samples over time, researchers hope to detect tumor DNA fragments that reflect how the cancer is behaving. The goal is to provide real-time signals about treatment effectiveness and emerging resistance, potentially guiding timely changes in care. The study blends clinical care with cutting-edge liquid biopsy methods to improve understanding of LMS biology and patient outcomes.
Why it matters
Potential benefit: If successful, it could lead to better timing of treatments and more personalized care for LMS patients.
How similar studies have gone: Liquid biopsy approaches have shown promise in other cancers, but LMS-specific data remain exploratory.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Crompton, Brian — University of Michigan at Ann Arbor
- Study coordinator: Crompton, Brian
Related research
Other NIH-funded projects on the same topics.
-
Towards a blood-based test using nanophotonic exosomes to screen and diagnose liver cancer
A new blood test using tiny particles shed by liver cancer cells aims to screen for hepatocellular carcinoma earlier and more accurately.
-
Liquid biopsy test to screen for lymphoma in people with HIV
A new blood test called High Density Methyl-Seq is being checked to see if it can detect lymphoma early in people living with HIV.
-
Liquid biopsy and oxygen therapy to guide glioblastoma treatment
A patient-focused study exploring a blood-based test and a safe oxygen therapy to help doctors tell true tumor growth from treatment effects in adults with glioblastoma treated with chemoradiation.
-
Imagnostix: a simple blood-based test to flag Alzheimer’s risk
A new blood-based test called Imagnostix aims to help identify people who may be developing Alzheimer’s disease earlier and more cheaply than current methods.
-
Multi-omic liquid biopsy to guide immunotherapy in colorectal and anal cancers
A patient-facing overview of a study testing blood-based biomarkers (ctDNA and extracellular RNA) to better tailor immunotherapy for colorectal and anal cancer patients.
-
RBC-based test to detect early NSCLC using blood-derived tumor DNA
A new blood test using red blood cells to find tumor DNA could help detect early non-small cell lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.